CO2022014452A2 - Formulaciones líquidas de análogos de glucagón - Google Patents
Formulaciones líquidas de análogos de glucagónInfo
- Publication number
- CO2022014452A2 CO2022014452A2 CONC2022/0014452A CO2022014452A CO2022014452A2 CO 2022014452 A2 CO2022014452 A2 CO 2022014452A2 CO 2022014452 A CO2022014452 A CO 2022014452A CO 2022014452 A2 CO2022014452 A2 CO 2022014452A2
- Authority
- CO
- Colombia
- Prior art keywords
- glucagon analogs
- liquid formulations
- formulations
- relates
- present
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 3
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a formulaciones de análogos de glucagón, o una sal farmacéuticamente aceptable del mismo y/o un derivado del mismo; y su uso médico, por ejemplo, en el tratamiento de la hipoglucemia. En particular, la presente invención se refiere a formulaciones líquidas acuosas estables de análogos de glucagón que comprenden combinaciones de excipientes que los hacen adecuados para el almacenamiento a largo plazo como líquidos, y pueden ser usados en formulaciones de dosis única (SD) o de dosis múltiples (MD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20163408 | 2020-03-16 | ||
| PCT/EP2021/056651 WO2021185821A1 (en) | 2020-03-16 | 2021-03-16 | Liquid formulations of glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014452A2 true CO2022014452A2 (es) | 2022-10-21 |
Family
ID=70008261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014452A CO2022014452A2 (es) | 2020-03-16 | 2022-10-11 | Formulaciones líquidas de análogos de glucagón |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20210283053A1 (es) |
| EP (1) | EP4121003B1 (es) |
| JP (1) | JP7834025B2 (es) |
| KR (1) | KR102956482B1 (es) |
| CN (1) | CN115279341B (es) |
| AR (1) | AR121581A1 (es) |
| AU (1) | AU2021236878B2 (es) |
| BR (1) | BR112022018462A2 (es) |
| CA (1) | CA3171184A1 (es) |
| CL (1) | CL2022002472A1 (es) |
| CO (1) | CO2022014452A2 (es) |
| ES (1) | ES3041327T3 (es) |
| HR (1) | HRP20251267T1 (es) |
| HU (1) | HUE073401T2 (es) |
| IL (1) | IL295977A (es) |
| MX (1) | MX2022011227A (es) |
| PE (1) | PE20230258A1 (es) |
| PH (1) | PH12022552457A1 (es) |
| PL (1) | PL4121003T3 (es) |
| RS (1) | RS67245B1 (es) |
| TW (1) | TW202200190A (es) |
| UA (1) | UA129439C2 (es) |
| WO (1) | WO2021185821A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005969A (es) * | 2022-05-30 | 2024-06-11 | Zealand Pharma As | Formulaciones liquidas de analogos de amilina. |
| WO2025056677A1 (en) | 2023-09-15 | 2025-03-20 | Zealand Pharma A/S | Dasiglucagon for use in the treatment of congenital hyperinsulinism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP2013523620A (ja) | 2010-03-26 | 2013-06-17 | ノヴォ ノルディスク アー／エス | 新規のグルカゴンアナログ |
| MX356957B (es) * | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| TN2017000349A1 (en) | 2015-02-17 | 2019-01-16 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| WO2019110838A1 (fr) * | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
-
2021
- 2021-03-16 PL PL21712156.5T patent/PL4121003T3/pl unknown
- 2021-03-16 BR BR112022018462A patent/BR112022018462A2/pt unknown
- 2021-03-16 ES ES21712156T patent/ES3041327T3/es active Active
- 2021-03-16 PE PE2022001968A patent/PE20230258A1/es unknown
- 2021-03-16 UA UAA202203796A patent/UA129439C2/uk unknown
- 2021-03-16 CA CA3171184A patent/CA3171184A1/en active Pending
- 2021-03-16 WO PCT/EP2021/056651 patent/WO2021185821A1/en not_active Ceased
- 2021-03-16 AR ARP210100659A patent/AR121581A1/es unknown
- 2021-03-16 RS RS20250960A patent/RS67245B1/sr unknown
- 2021-03-16 EP EP21712156.5A patent/EP4121003B1/en active Active
- 2021-03-16 CN CN202180021174.4A patent/CN115279341B/zh active Active
- 2021-03-16 HU HUE21712156A patent/HUE073401T2/hu unknown
- 2021-03-16 AU AU2021236878A patent/AU2021236878B2/en active Active
- 2021-03-16 US US17/203,126 patent/US20210283053A1/en not_active Abandoned
- 2021-03-16 MX MX2022011227A patent/MX2022011227A/es unknown
- 2021-03-16 KR KR1020227031361A patent/KR102956482B1/ko active Active
- 2021-03-16 JP JP2022555741A patent/JP7834025B2/ja active Active
- 2021-03-16 IL IL295977A patent/IL295977A/en unknown
- 2021-03-16 HR HRP20251267TT patent/HRP20251267T1/hr unknown
- 2021-03-16 TW TW110109431A patent/TW202200190A/zh unknown
- 2021-03-16 PH PH1/2022/552457A patent/PH12022552457A1/en unknown
-
2022
- 2022-09-09 CL CL2022002472A patent/CL2022002472A1/es unknown
- 2022-10-11 CO CONC2022/0014452A patent/CO2022014452A2/es unknown
-
2024
- 2024-12-20 US US18/989,423 patent/US20250195424A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20251267T1 (hr) | 2025-12-05 |
| WO2021185821A1 (en) | 2021-09-23 |
| EP4121003B1 (en) | 2025-08-06 |
| TW202200190A (zh) | 2022-01-01 |
| NZ791927A (en) | 2025-09-26 |
| CN115279341A (zh) | 2022-11-01 |
| PH12022552457A1 (en) | 2023-12-11 |
| CA3171184A1 (en) | 2021-09-23 |
| RS67245B1 (sr) | 2025-10-31 |
| ES3041327T3 (en) | 2025-11-11 |
| EP4121003C0 (en) | 2025-08-06 |
| KR102956482B1 (ko) | 2026-04-23 |
| UA129439C2 (uk) | 2025-04-23 |
| AU2021236878B2 (en) | 2025-09-11 |
| HUE073401T2 (hu) | 2026-01-28 |
| KR20220154110A (ko) | 2022-11-21 |
| MX2022011227A (es) | 2022-10-07 |
| JP7834025B2 (ja) | 2026-03-23 |
| CL2022002472A1 (es) | 2023-02-17 |
| BR112022018462A2 (pt) | 2022-11-01 |
| AR121581A1 (es) | 2022-06-15 |
| EP4121003A1 (en) | 2023-01-25 |
| US20250195424A1 (en) | 2025-06-19 |
| AU2021236878A1 (en) | 2022-09-29 |
| JP2023518052A (ja) | 2023-04-27 |
| PL4121003T3 (pl) | 2026-02-23 |
| CN115279341B (zh) | 2026-03-31 |
| PE20230258A1 (es) | 2023-02-07 |
| US20210283053A1 (en) | 2021-09-16 |
| IL295977A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012884A (es) | Terapia de combinacion. | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| MX2024005304A (es) | Derivado del acido fenilpropionico sustituido y uso del mismo. | |
| CL2022002472A1 (es) | Formulaciones líquidas de análogos de glucagón | |
| CL2011002634A1 (es) | Disolucion acuosa sin alcohol etilico que comprende propanolol o una sal farmaceuticamente aceptable del mismo, un edulcorante tipo no azucarado y menos del 0,01 % (p/v) de un agente conservante; procedimiento de preparacion; uso de la disolucion en el tratamiento de hemangiomas. | |
| CL2021000678A1 (es) | Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2) | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CO2023015528A2 (es) | Estimuladores de guanilil ciclasa soluble (sgc) | |
| NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
| AR102248A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| CO2022004572A2 (es) | Tratamiento de la diabetes mellitus tipo 2 | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| CL2017001629A1 (es) | Formulaciones inyectables de paracetamol. | |
| AR105503A1 (es) | Concentrado que contiene alprostadil | |
| MX2023013650A (es) | Compuesto usado como inhibidor de bcr abl. |